Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform.
The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market.
'Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT,' said Intalight chairman and Founder, Shawn Peng. 'This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients.'
DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous.
'Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth,' said Intalight CEO and Co-Founder, Bing Li. 'DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know.'
Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices.
'This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US,' remarked Intalight Chief Commercial Officer, Joe Garibaldi. 'We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval.'
As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia.
About Intalight
Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at https://www.intalight.com and follow us on LinkedIn and Facebook.
View original content to download multimedia: https://www.prnewswire.com/news-releases/intalight-receives-ce-mark-for-its-progressive-dream-oct-swept-source-imaging-302454390.html
SOURCE Intalight Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
38 minutes ago
- Business Wire
University of Phoenix and Jobs for the Future Partner to Help Employers Harness Effective Upskilling and Reskilling at Scale
PHOENIX--(BUSINESS WIRE)-- University of Phoenix and Jobs for the Future (JFF), a national nonprofit driving transformation in the U.S. workforce and education systems, announce a new project in their continued partnership; to pilot and evaluate an AI-powered skills analysis and upskilling business outcomes strategy that accurately captures and understands employee skills, tech integration and employer adoption of skills pathways for their workforce. The collaboration comes at a pivotal moment. According to the World Economic Forum, 39% of core job skills are expected to change by 2030. Yet many organizations still do not center understanding of workforce skills and development opportunities in their business strategy; the 2025 Career Optimism Index® study found that while 86% of workers are actively seeking skill development opportunities, employer investment in reskilling and upskilling has declined by 13 and 10 points, respectively, since 2022. 'As AI reshapes the workforce, the companies that thrive won't necessarily be those with the best technology, but those with the most adaptable people,' said Raghu Krishnaiah, Chief Operating Officer at University of Phoenix. 'We seek to close the gap between aspiration and action by effective implementation of a business strategy that centers the skills needed for the success of the organization and embeds learning and career pathways for employees based on their skillsets.' The project aims to uncover how skills-focused, AI-enabled tools can drive better outcomes in employee development, retention, and mobility—while also addressing critical issues like algorithmic transparency and data accountability. With support from University of Phoenix, JFF will conduct discovery and analysis, including exploration of strategies that create impact through skills validation and upskilling; and then through piloting, testing and market experience with employers that feature diversely skilled workforce populations. The initiative will conduct analysis and testing with the University's technology affiliate, Skillmore™, an AI skills intelligence platform, in collaboration with employers. 'During this critical adoption phase of AI technology platforms by companies, JFF is deeply committed to a thorough examination of these platforms to better understand employer and employee impact, as well as to support responsible AI design,' states Alison Lands, Vice President, Employer & Workforce Solutions, JFF. 'This initiative allows us to co-design solutions that are innovative and responsive to the needs of a broad and evolving workforce.' The shared project highlights mission alignment between the two organizations in supporting working adult learners: JFF has established a North Star that by 2033, 75 million people facing barriers to economic advancement will have quality jobs, and the mission of University of Phoenix is to provide access to higher education opportunities that enable students to develop the knowledge and skills necessary to achieve their professional goals, improve the performance of their organizations and provide leadership and service to their communities. 'Our work with JFF is about turning good intentions around learning and development into real, measurable progress, allowing us to build greater confidence in AI-generated recommendations and make transparent technology's role in promoting talent mobility,' shares Krishnaiah. 'Together, we can help employers unlock vital support services for creating holistic talent solutions and career pathways for the learners and workers we aim to serve.' The partnership highlights the University's collaboration with 2,000+ employers through its Adaptable Skills Solutions, offering customized workforce assessments in partnership with the University's technology affiliate Skillmore TM for a transformational combination with professional development and discounted education benefits. Skillmore TM is a trademark of Talent Mobility, Inc. Talent Mobility, Inc. (dba Skillmore) is an affiliate of University of Phoenix and requires a separate agreement for its services. The project will run through May 2026 and culminate in a field-facing impact report offering actionable insights for employers, educators, and technology developers. About University of Phoenix University of Phoenix innovates to help working adults enhance their careers and develop skills in a rapidly changing world. Flexible schedules, relevant courses, interactive learning, skills-mapped curriculum for our bachelor's and master's degree programs and a Career Services for Life® commitment help students more effectively pursue career and personal aspirations while balancing their busy lives. . JFF is building a future that works for everyone by transforming U.S. education and workforce systems to drive economic success for people, businesses, and communities. Learn more at
Business Wire
2 hours ago
- Business Wire
GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025
CHICAGO--(BUSINESS WIRE)--GE HealthCare's commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. 'Flyrcado represents one of the most significant advancements in nuclear cardiology in decades,' shares Marcelo Fernando DiCarli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Executive Director, Cardiovascular Share As cardiovascular disease (CVD) continues to rise globally, i the need for advanced diagnostic technologies becomes increasingly critical. GE HealthCare's molecular imaging technologies – including positron emission tomography-computed tomography (PET/CT) and single-photon emission computed tomography-computed tomography (SPECT/CT) – and radiopharmaceuticals – namely its Flyrcado™ (flurpiridaz F 18) injection – play a crucial role in cardiac care by providing detailed insights into biological processes beyond conventional imaging. These advanced imaging techniques enable early diagnosis, precise assessment of myocardial perfusion and ischemia, and evaluation of infiltrative cardiomyopathies. By identifying specific pathologic processes, molecular imaging helps tailor treatments to individual patients, with the aim to enhance the effectiveness of therapies and improving prognosis. Additionally, it allows for monitoring treatment responses and disease progression, ultimately helping contribute to better patient outcomes. ii 'Flyrcado represents one of the most significant advancements in nuclear cardiology in decades,' shares Marcelo Fernando DiCarli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Executive Director, Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women's Hospital. 'For the first time in nearly 20 years, we have a new PET myocardial perfusion tracer that brings the latest imaging technology within reach for patients across the U.S. The image quality is exceptional, and its use has the potential to reduce unnecessary invasive procedures by improving diagnostic confidence. I've found it to be a valuable addition to our clinical practice, enabling more personalized treatment strategies and better patient outcomes. The excitement across the cardiology community is evident as we enter a new era in precision cardiac care.' GE HealthCare's Flyrcado injection, a first-of-its-kind F 18-unit dose PET myocardial perfusion imaging (MPI) agent for patients with known or suspected coronary artery disease (CAD), helps clinicians deliver higher diagnostic efficacy compared to SPECT MPI, the predominant procedure used in nuclear cardiology today. Recently launched in select U.S. markets, Flyrcado's availability aligns with its receipt of CMS pass-through status, effective April 1, which includes a drug-specific HCPCS billing code to support efficient coding and Medicare coverage. In addition, Flyrcado is now covered by all seven Medicare Administrative Contractors (MACs) at either invoice price or better, depending on the site of care. More than 50% of commercially insured beneficiaries are now covered under updated national and regional cardiac PET policies that include Flyrcado as a covered benefit—marking significant progress in expanding access beyond the hospital outpatient setting. Further expansion is expected in the second half of the year as additional payors complete their policy reviews. To support this evolving access landscape, GE HealthCare has launched the Flyrcado Support Center (800-729-0701) to assist customers with benefits investigations, coding, coverage, and claims submissions. 'With coverage now in place for all traditional Medicare beneficiaries, along with updated PET coverage policies in place for more than half of the nation's commercially insured beneficiaries, millions of Americans—many at risk for or living with coronary artery disease, the leading cause of death in the U.S.—will have greater access to this innovative technology,' said Eric Ruedinger, Vice President and General Manager of GE HealthCare's Pharmaceutical Diagnostics division for the U.S. and Canada. 'Flyrcado represents a significant advancement in cardiac care over SPECT imaging, offering clinicians a new, highly effective diagnostic tool to support more timely and personalized care for patients with known or suspected coronary artery disease.' Flyrcado can be imaged with a range of PET/CT systems, including GE HealthCare's Omni Legend, offering clinicians flexibility in integrating this innovative tracer into their existing imaging workflows. With Flyrcado, clinicians have the first practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD, providing a highly effective protocol for evaluating ischemia in patients. Beyond Flyrcado, Omni Legend enables exceptional cardiac diagnostics, accommodating a range of tracers – including fast decay and emerging tracers. Representing a scalable PET/CT platform designed to evolve with healthcare system needs across care areas with shorter scan times and lower doses, iii it continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. iv GE HealthCare is also proud to provide its StarGuide and Aurora SPECT/CT systems, designed to capture gamma rays emitted by radioactive tracers. Both systems offer exceptional image quality and scan time efficiency, supporting clinicians in making confident diagnoses. These features make SPECT/CT a valuable tool in cardiac care, providing comprehensive views of both physiological and structural aspects of diseases. Additional solutions from GE HealthCare's MIM Software are also available to enable multi-modality viewing and fusion of cardiac images and offer integration pathways for cardiac analysis. A devoted provider of cardiology solutions, GE HealthCare supports the continuum of care and personalized treatments for the world's largest hospitals to the smallest clinics and beyond the walls of the clinician's office. With a vast and diversified portfolio, GE HealthCare offers healthcare professionals a breadth of solutions from early detection and diagnosis, to planning, intervention, and monitoring to help clinicians deliver better patient outcomes in cardiology care today and for the future. For more information on GE HealthCare's innovative portfolio of molecular solutions for cardiology, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. Forward-looking statements This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as 'will,' 'expect,' 'may,' 'would,' 'could,' 'plan,' 'believe,' 'anticipate,' 'intend,' 'potential,' and similar expressions. These forward-looking statements may include, but are not limited to, statements about Flyrcado and GE HealthCare Technologies Inc.'s (the 'Company's') performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, uncertainties regarding the commercial success of Flyrcado, the Company's ability to receive pass-through status from the US Centers for Medicaid and Medicare, and decisions by regulatory authorities impacting labeling, manufacturing processes, safety, or other matters that could affect the availability or commercial potential of Flyrcado. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information Indications and usage FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Contraindications None Warnings and precautions Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information. Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void. Adverse reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. Use in specific populations Pregnancy There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure. FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy. Lactation Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration. Pediatric Use Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
Business Upturn
3 hours ago
- Business Upturn
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
Sydney, Australia: As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
